Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections
Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of Monoclonal Antibodies and Applications of Machine Learning to Predict Aerosol Performance of Dry Powders for Inhalation
FORT WORTH, Texas, Sept. 22, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of multiple abstracts featuring application of the Company’s Thin Film Freezing Technology at the upcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting, which is being held in Boston from October 16-19, 2022. Research from two abstracts has been selected for presentation as part of the “Special Poster Collections” at the meeting.
The research being presented was led by colleagues in the laboratory of Dr. Robert O. Williams III, Thin Film Freezing inventor and Special Advisor to TFF, at the University of Texas at Austin. The results highlight the broad applicability of Thin Film Freezing, including the ability to produce stable, aerosolizable dry powder formulations of monoclonal antibodies for lung delivery, and also demonstrate how the application of deep learning methods such as machine learning and artificial intelligence can be used to efficiently develop and measure the aerosol performance of powders made via Thin Film Freezing. As TFF continues to expand its network of collaborations in biologics, the research being done by Dr. Williams and colleagues will guide the company’s knowledge-building and ongoing progress.
Presentation details are as follows:
“Applications of Deep Learning to Predict Aerosol Performance of Dry Powders for Inhalation”
Tuesday, October 18, 2022, 10:30-11:30 AM ET
“Inhalation Dry Powders of Monoclonal Antibodies Made by Thin-Film Freeze-Drying”
Wednesday, October 19, 2022, 10:30-11:30 AM ET
Scientists in Dr. Williams’ lab will also present four additional posters at the conference, highlighting the applicability of Thin Film Freezing in alternative formulations for nicotine, antiviral treatments for COVID-19 and other areas. Full details on the data being presented can be found on the conference website.
ABOUT AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS (AAPS)
Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide.
ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING TECHNOLOGY PLATFORM
TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert any drug, including vaccines, small and large molecules and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its continued development of Voriconazole Inhalation Powder, Tacrolimus Inhalation Powder, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its Voriconazole Inhalation Powder, Tacrolimus Inhalation Powder or any of its other dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s 2021 Annual Report on Form 10-K filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Relations Contact: Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577 cdavis@lifesciadvisors.com
Media Contact: Gwendolyn Schanker LifeSci Communications (269) 921-3607 gschanker@lifescicomms.com
Asteroid impact triggered the biggest earthquakes experienced by our planet during this era
Omicron variants are becoming increasingly similar. It could make them easier to fight—or harder to control.
The Star Trek celeb describes in a new book his unexpected feeling of "overwhelming sadness" at the edge of space.
SpaceX's 46th launch so far this year put two Intelsat Galaxy communications satellites in orbit.
Two meteor showers will grace October’s skies, beginning with the Draconid meteors peaking on Sunday and Monday
"Mission Impossible" star Tom Cruise is slated to head into space to film a movie with "The Bourne Identity" director Doug Liman.
SpaceX's Falcon 9 liftoff on Saturday, Oct. 8, at 7:05 p.m. EDT from Cape Canaveral Space Force Station marks Florida's 44th launch this year.
Columbus Day arrives this year after investors navigated choppy waters last week. The marked its largest two-day gain since April 2020 on Tuesday, after a weak ISM manufacturing activity report and other economic data suggested the Federal Reserve might ease future interest-rate hikes. This week, investors can expect third-quarter earnings results, the September consumer price index reading, and other macro data to give better clues as to whether the Fed will be able to negotiate a soft landing or plunge the U.S. into a recession.
(Bloomberg) -- US restrictions on China’s access to advanced American technologies could slash growth of the country’s largest chipmaker by half next year, Bloomberg Intelligence estimates.Most Read from BloombergUkraine Latest: Putin Calls Security Meeting, Comments on BridgeEight Years of Combat Hardened Ukraine’s Army Into a Fighting ForceRussia Races to Reopen Crimea Bridge Damaged in Fiery BlastRussia Blitzes Ukraine After Putin Blames Kyiv for Bridge BlastSemiconductor Manufacturing Intern
An already strained U.S. stock market will be further challenged in the week ahead as the government publishes a key inflation report and megabanks kick off what’s likely to be a murky earnings season.
Paylocity and three other top-ranked software stocks in the IBD 50 have seen bullish price action in recent weeks.
The problems that both protocols suffered are reminders that neither is really decentralized, and that they are not yet true challengers to Ethereum; ether and other altcoins trade sideways.
While British households head into a winter of soaring energy costs, a tumbling currency and nearly double-digit inflation, the country's banks are in line for a handsome payday as mortgage prices spike after a decade of stagnation. Banks are finding the home loan market stacked in their favour after years of low mortgage rates, but are also aware that bigger mortgage bills could spell trouble for cash-strapped customers. Some investors and analysts are already questioning whether banks' risk models are up to the task of identifying loans that will turn a profit from those which could cost lenders dearly in the long run.
Stocks surged 5.7% on Monday and Tuesday and then shed almost all of those gains on Wednesday, Thursday, and Friday.
(Bloomberg) -- There’s a global migration underway in the gold market, as western investors dump bullion while Asian buyers take advantage of a tumbling price to snap up cheap jewelry and bars.Most Read from BloombergUkraine Latest: Putin Calls Security Meeting, Comments on BridgeEight Years of Combat Hardened Ukraine’s Army Into a Fighting ForceRussia Races to Reopen Crimea Bridge Damaged in Fiery BlastRussia Blitzes Ukraine After Putin Blames Kyiv for Bridge BlastRising rates that make gold le
BENGALURU (Reuters) -Shares of India's Tata Motors Ltd fell as much as 4.6% on Monday after its Jaguar Land Rover (JLR) business wholesale volumes fell below expectations, prompting top brokerages to cut price targets and also warn of a slowdown next year. Tata Motors on Friday said JLR wholesale volumes - excluding its joint venture in China - were 75,307 for the second quarter, while it had in August, projected wholesale volumes to be around 90,000. The automaker, among the largest in the country, blamed lower-than-expected supply of specialised chips from one supplier for failing to meet its target.
(Bloomberg) -- The Philippine central bank may require banks to provide more documents to support foreign-exchange transactions and to increase reporting frequency amid the local currency’s excessive volatility.Most Read from BloombergUkraine Latest: Putin Calls Security Meeting, Comments on BridgeRussia Races to Reopen Crimea Bridge Damaged in Fiery BlastEight Years of Combat Hardened Ukraine’s Army Into a Fighting ForcePutin Orders Sakhalin-1 Project Transferred to Russian Entity“The central b
Edgar Wachenheim III’s Greenhaven Associates added to positions in Citigroup and PulteGroup, and initiated positions in Oshkosh and Gildan in the third quarter.
It may not be practical — at least for now.
(Bloomberg) -- Shares tumbled Monday amid intensifying concern over rising global interest rates and as Chinese investors returned from a week-long holiday to tighter restrictions on American technology.Most Read from BloombergUkraine Latest: Putin Calls Security Meeting, Comments on BridgeRussia Races to Reopen Crimea Bridge Damaged in Fiery BlastEight Years of Combat Hardened Ukraine’s Army Into a Fighting ForcePutin Orders Sakhalin-1 Project Transferred to Russian EntityA gauge of Asian equit